The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ:ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
The regulatory approval was supported by positive clinical results from HELIOS-A Phase 3 study that evaluated the efficacy and safety of AMVUTTRA across a diverse group of patients with hATTR amyloidosis with polyneuropathy.
